ReNerve (ASX:RNV) - Stock Price, News & Analysis

RNV Stock Overview

A medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. More details

RNV fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue grew by 38% over the past year

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (A$177K)

Does not have a meaningful market cap (A$19M)

ReNerve Limited Competitors

Lumos Diagnostics Holdings

ASX:LDX

AU$24.6m

Next Science

ASX:NXS

AU$41.6m

Visioneering Technologies

ASX:VTI

AU$7.7m

Osteopore

ASX:OSX

AU$4.3m

Price History & Performance

Summary of all time highs, changes and price drops for ReNerve
Historical stock prices
Current Share Price	AU$0.20
52 Week High	AU$0
52 Week Low	AU$0
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RNV	AU Medical Equipment	AU Market
7D	n/a	0.5%	1.5%
1Y	n/a	14.2%	17.2%

Return vs Industry: Insufficient data to determine how RNV performed against the Australian Medical Equipment industry.

Return vs Market: Insufficient data to determine how RNV performed against the Australian Market.

Price Volatility

Is RNV's price volatile compared to industry and market?
RNV volatility
RNV Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: RNV's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine RNV's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Julian Chick	renerve.com.au

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a protective wrap used to protect repaired injured nerves; NervAlign Nerve Graft, a size-based range of off-the-shelf nerve grafts for the repair of damaged nerves; and NervAlign bionic nerve to produce a replacement nerve that contains shaped ionic polymers, which would enable the stimulation of the distal end of a nerve injury. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

ReNerve Limited Fundamentals Summary

How do ReNerve's earnings and revenue compare to its market cap?
RNV fundamental statistics
Market cap	AU$19.17m
Earnings (TTM)	-AU$2.98m
Revenue (TTM)	AU$177.37k

108.1x

P/S Ratio

-6.4x

P/E Ratio

Is RNV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNV income statement (TTM)
Revenue	AU$177.37k
Cost of Revenue	AU$623.00
Gross Profit	AU$176.75k
Other Expenses	AU$3.16m
Earnings	-AU$2.98m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	99.65%
Net Profit Margin	-1,682.86%
Debt/Equity Ratio	0%

How did RNV perform over the long term?

See historical performance and comparison